BRAF(V600E) mutation and the biology of papillary thyroid cancer

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 191-205

  Frasca, F ^a   Nucera, C ^b   Pellegriti, G ^a   Gangemi, P ^c   Attard, M ^d   Stella, M ^d   Loda, M ^e   Vella, V ^a   Giordano, C ^f   Trimarchi, F ^b   Mazzon, E ^b   Belfiore, A ^g   Vigneri, R ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Policlin Universitario P Giaccone   (Italy)

^g UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARCINOGEN; GELATINASE B; IODINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER INVASION; CERVICAL LYMPH NODE; ENVIRONMENTAL FACTOR; FEMALE; GENDER; GENE MUTATION; GENETIC ASSOCIATION; GEOGRAPHY; HUMAN; HUMAN TISSUE; ITALY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PAPILLARY THYROID CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; THYROID CANCER; TUMOR VOLUME; UNIVARIATE ANALYSIS;

CARCINOMA, PAPILLARY; DISEASE PROGRESSION; DNA PRIMERS; FEMALE; FOLLOW-UP STUDIES; GEOGRAPHY; HUMANS; IMMUNOENZYME TECHNIQUES; LASERS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 9; MICRODISSECTION; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SICILY; THYROID NEOPLASMS;

EID: 41349122686     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0212     Document Type: Article

References (84)

1. Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N & Yamashita S 2007 Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. International Journal of Cancer 120 196-200.
2. Akslen LA, Haldorsen T, Thoresen SO & Glattre E 1993 Incidence pattern of thyroid cancer in Norway: influence of birth cohort and time period. International Journal of Cancer 53 183-187.
3. Arnbjornsson E, Arnbjornsson A & Olafsson A 1986 Thyroid cancer incidence in relation to volcanic activity. Archives of Environmental Health 41 36-40.
4. Baloch ZW, Mandel S & LiVolsi VA 2001 Combined tall cell carcinoma and Hurthle cell carcinoma (collision tumor) of the thyroid. Archives of Pathology & Laboratory Medicine 125 541-543.
5. Barbara D, Simi U, Meucci G, Lapi P, Orsini P & Pasquini C 2005 Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers - are they different diseases? Clinical Endocrinology 63 577-581.
6. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D & Westra WH 2004 BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology 17 1359-1363.
7. Belfiore A, La Rosa GL, Padova G, Sava L, Ippolito O & Vigneri R 1987 Prevalence of cold thyroid nodules and thyroid malignancies in patients from an iodine deficient area. Cancer 60 3096-3102.
8. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, Regalbuto C & Vigneri R 1992 Cancer risk in patients with cold thyroid nodules. Relevance of iodine intake, sex, age and multinodularity. American Journal of Medicine 93 363-369.
9. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA & Nikiforov YE 2005 Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. Journal of Clinical Investigation 115 94-101.
10. Cimino G & Toscano G 1998 Dissolution of trace metals from lava ash: influence on the composition of rainwater in the Mount Etna volcanic area. Environmental Pollution 99 389-393.
11. Colonna M, Grosclaude P, Remontet L, Schvartz C, Mace-Lesech J, Velten M, Guizard A, Tretarre B, Buemi AV, Arveux P et al. 2002 Incidence of thyroid cancer in adults recorded by French cancer registries. European Journal of Cancer 38 1762-1768.
12. Comba P, Gianfagna A & Paoletti L 2003 Pleural mesothelioma cases in Biancavilla are related to a new fluoro-edenite fibrous amphibole. Archives of Environmental Health 58 229-232.
13. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J & Rapp UR 1994 The ins and outs of Raf kinases. Trends in Biochemical Sciences 19 474-480.
14. Delange F, Vigneri R, Trimarchi F, Filetti S, Pezzino V, Squatrito S, Bourdoux P & Ermans AM 1978 Etiological factors of endemic goiter in north-eastern Sicily. Journal of Endocrinological Investigation 1 137-142.
15. Dobert N, Menzel C, Oeschger S & Grunwald F 2004 Differentiated thyroid carcinoma: the new UICC. 6th ed. TNM classification system in a retrospective analysis of 169 patients. Thyroid 14 65-70.
16. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A et al. 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 92 2840-2843.
17. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 91 179-184.
18. Farahati J, Geling M, Mader U, Mortl M, Luster M, Muller JG, Flentje M & Reiners C 2004 Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995. Thyroid 14 141-147.
19. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L & Beck-Peccoz P 2004 BRAF mutations in an Italian cohort of thyroid cancers. Clinical Endocrinology 61 239-243.
20. V600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer 13 455-464.
21. Garnett MJ & Marais R 2004 Guilty as charged: BRAF is a human oncogene. Cancer Cell 6 313-319.
22. Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, Berti P, Materazzi G, Miccoli P, Santoro M et al. 2007 The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 92 3511-3516.
23. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K et al. 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 6646-6656.
24. Gomez Segovia I, Gallowitsch HJ, Kresnik E, Kumnig G, Igerc I, Matschnig S, Stronegger WJ & Lind P 2004 Descriptive epidemiology of thyroid carcinoma in Carinthia, Austria: 1984-2001. Histopathologic features and tumor classification of 734 cases under elevated general iodination of table salt since 1990: population-based age-stratified analysis on thyroid carcinoma incidence. Thyroid 14 277-286.
25. Hernandez BY 2003 Highlights of recent cancer incidence data in Hawaii. Hawaii Medical Journal 62 17-18.
26. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG & Edwards BK 2001 Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. Journal of the National Cancer Institute 93 824-842.
27. Ito Y, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K & Miyauchi A 2005 Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 68 87-96.
28. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K & Miyauchi A 2006 Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World Journal of Surgery 30 780-786.
29. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR & Lloyd RV 2006 BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagnostic Molecular Pathology 15 136-143.
30. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK et al. 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 3667-3670.
31. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B & Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery 246 466-471.
32. Kim KH, Kang DW, Kim SH, Seong IO & Kang DY 2004 Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Medical Journal 45 818-821.
33. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ & Shong YK 2005 The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clinical Endocrinology 63 588-593.
34. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D & Hoon DS 2006a Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Annals of Surgery 244 799-804.
35. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ et al. 2006b The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clinical Endocrinology 65 364-368.
36. Knudsen N, Laurberg P, Perrild H, Bulow I, Ovesen L & Jorgensen T 2002 Risk factors for goiter and thyroid nodules. Thyroid 12 879-888.
37. Kolonel LN 1985 Cancer incidence among Filipinos in Hawaii and the Philippines. National Cancer Institute Monographs 69 93-98.
38. Lee JH, Lee ES, Kim YS, Won NH & Chae YS 2006 BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 38 201-204.
39. Lee JH, Lee ES & Kim YS 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110 38-46.
40. Leenhardt L, Grosclaude P & Cherie-Challine L 2004 Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14 1056-1060.
41. Lin JD, Chen ST, Chao TC, Hsueh C & Weng HF 2005 Diagnosis and therapeutic strategy for papillary thyroid micro carcinoma. Archives of Surgery 140 940-945.
42. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC & Cheng JT 2005 No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clinical Endocrinology 63 461-466.
43. Lo CY, Chan WF, Lang BH, Lam KY & Wan KY 2006 Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World Journal of Surgery 30 752-758.
44. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P et al. 2007 Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 92 4085-4090.
45. Maeta H, Ohgi S & Terada T 2001 Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Archiv 438 121-128.
46. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M et al. 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 115 1068-1081.
47. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF & Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Research 66 6521-6529.
48. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D et al. 2007 Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Molecular Cancer Therapeutics 6 1070-1078.
49. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, Qian X, Sebo TJ, Erickson LA & Lloyd RV 2005 RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Laboratory Investigation 85 1065-1075.
50. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397.
51. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocrine Pathology 13 3-16.
52. Nikiforov YE 2004 Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 15 319-327.
53. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404.
54. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD et al. 2004 Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters 209 1-6.
55. Oler G, Ebina KN, Michaluart P Jr, Kimura ET & Cerutti J 2005 Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clinical Endocrinology 62 509-511.
56. V600E promotes invasiveness of thyroid cancer cells through nuclear factor κB activation. Endocrinology 147 5699-5707.
57. Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, Jang HC, Park SH, Park do J & Cho BY 2006 Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 107 1831-1838.
58. Pelizzo MR, Boschin IM, Toniato A, Pagetta C, Piotto A, Bernante P, Casara D, Pennelli G & Rubello D 2004 Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nuclear Medicine Communications 25 547-552.
59. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R & Belfiore A 2004 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. Journal of Clinical Endocrinology and Metabolism 89 3713-3720.
60. Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M, Oakley K, Turtle RM & Francis G 2005 BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 15 320-325.
61. Peyssonnaux C & Eychene A 2001 The Raf/MEK/ERK pathway: new concepts of activation. Biology of the Cell 93 53-62.
62. Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M & Thomas G 2005 Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. Journal of Pathology 205 558-564.
63. Puxeddu E, Moretti S, Giannico A, Martinelli M, Marino C, Avenia N, Cristofani R, Farabi R, Reboldi G, Ribacchi R et al. 2003 Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. European Journal of Endocrinology 148 505-513.
64. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G et al. 2004 BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 89 2414-2420.
65. Quiros RM, Ding HG, Gattuso P, Prinz RA & Xu X 2005 Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103 2261-2268.
66. Regalbuto C, Squatrito S, La Rosa GL, Cercabene G, Ippolito A, Tita P, Salamone S & Vigneri R 1996 Longitudinal study on goiter prevalence and goitrogen factors in northeastern Sicily. Journal of Endocrinological Investigation 19 638-645.
67. - targeting to the membrane. Endocrine-Related Cancer 13 257-269.
68. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A & Giordano C 2007 BRAF(V600E) mutation and p27(kip1) expression in papillary carcinomas of the thyroid 1 cm and their paired lymph node metastases. Cancer 110 1218-1226.
69. Rosenbaum E, Hosler G, Zahurak M, Cohen Y, Sidransky D & Westra WH 2005 Mutational activity of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Modern Pathology 18 898-902.
70. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N et al. 1992 Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. Journal of Clinical Investigation 89 1517-1522.
71. Santoro M, Melillo RM, Carlomagno F, Fusco A & Vecchio G 2002a Molecular mechanisms of RET activation in human cancer. Annals of the New York Academy of Sciences 963 116-121.
72. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A et al. 2002b RET activation and clinicopathologic features in poorly differentiated thyroid tumors. Journal of Clinical Endocrinology and Metabolism 87 370-379.
73. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G & Vitale M 2006 Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). European Journal of Endocrinology 154 341-348.
74. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, Lushnikov E, Kumagai A, Nakashima M, Meirmanov S et al. 2004 The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. International Journal of Oncology 25 1729-1735.
75. Tronko MD, Howe GR, Bogdanova TI, Bouville AC, Epstein OV, Brill AB, Likhtarev IA, Fink DJ, Markov VV, Greenebaum E et al. 2006 A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. Journal of the National Cancer Institute 98 897-903.
76. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM & Sobrinho-Simoes M 2004 BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology 202 247-251.
77. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM et al. 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv 446 589-595.
78. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF & de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. Journal of Clinical Endocrinology and Metabolism 88 2745-2752.
79. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, Trink B & Xing M 2005 High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. Journal of Clinical Endocrinology and Metabolism 90 5265-5269.
80. Vigneri R 1988 Studies on the goiter endemia in Sicily. Journal of Endocrinological Investigation 11 831-843.
81. Xing M 2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262.
82. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762.
83. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6379.
84. Zwi LJ & LiVolsi VA 2002 Hurthle cell carcinoma arising from thyroid papillary carcinoma. Endocrine Pathology 13 213-217.